Arbutus Biopharma Corp. Announces Board and Executive Changes

Ticker: ABUS · Form: 8-K · Filed: 2025-04-03T00:00:00.000Z

Sentiment: neutral

Topics: governance, executive-compensation, board-changes

Related Tickers: ABUS

TL;DR

Arbutus Biopharma (ABUS) filed an 8-K detailing director departures, new elections, and executive pay adjustments.

AI Summary

Arbutus Biopharma Corp. announced on March 28, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of directors, the election of new directors, and adjustments to compensatory arrangements for certain officers. These events are detailed in their Form 8-K filing.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial priorities, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in board and executive leadership can introduce uncertainty regarding future strategy and operational direction.

Key Players & Entities

FAQ

What specific reasons were given for the departure of directors?

The filing indicates the departure of directors but does not specify the reasons in the provided text.

Who are the newly elected directors?

The filing states that directors were elected, but their names are not listed in the provided excerpt.

What specific compensatory arrangements were adjusted for officers?

The filing mentions adjustments to compensatory arrangements for certain officers, but the details of these arrangements are not included in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on March 28, 2025.

What is Arbutus Biopharma Corp.'s former company name?

Arbutus Biopharma Corp.'s former company names include TEKMIRA PHARMACEUTICALS Corp.

From the Filing

0001447028-25-000093.txt : 20250403 0001447028-25-000093.hdr.sgml : 20250403 20250403161133 ACCESSION NUMBER: 0001447028-25-000093 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250328 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events FILED AS OF DATE: 20250403 DATE AS OF CHANGE: 20250403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 25809547 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 abus-20250328.htm 8-K abus-20250328 FALSE 0001447028 701 Veterans Circle Warminster Pennsylvania 0001447028 2025-03-28 2025-03-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  March 28, 2025 Arbutus Biopharma Corp oration (Exact name of registrant as specified in its charter)   British Columbia, Canada   001-34949   98-0597776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   701 Veterans Circle Warminster , Pennsylvania   18974 (Address of principal executive offices)   (Zip Code)   ( 267 ) 469-0914 Registrant’s telephone number, including area code     (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Shares, without par value   ABUS   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Karen Sims Post-Termination Agreements As previously disclosed, Arbutus Biopharma Corporation (the “Comp

View on Read The Filing